+

WO1997009343A3 - Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers - Google Patents

Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers Download PDF

Info

Publication number
WO1997009343A3
WO1997009343A3 PCT/FR1996/001340 FR9601340W WO9709343A3 WO 1997009343 A3 WO1997009343 A3 WO 1997009343A3 FR 9601340 W FR9601340 W FR 9601340W WO 9709343 A3 WO9709343 A3 WO 9709343A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
treatment
oncogenic activity
antagonists
protein mdm2
Prior art date
Application number
PCT/FR1996/001340
Other languages
English (en)
Other versions
WO1997009343A2 (fr
Inventor
Bruno Tocque
Marie-Christin Dubs-Poterszman
Bohdan Wasylyk
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Bruno Tocque
Dubs Poterszman Marie Christin
Bohdan Wasylyk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK96930195T priority Critical patent/DK0848720T3/da
Priority to EP96930195A priority patent/EP0848720B1/fr
Priority to DE69631335T priority patent/DE69631335T2/de
Priority to SK280-98A priority patent/SK287127B6/sk
Priority to IL123514A priority patent/IL123514A/en
Priority to CA2228667A priority patent/CA2228667C/fr
Priority to JP9510900A priority patent/JPH11511980A/ja
Priority to SI9630666T priority patent/SI0848720T1/xx
Priority to BR9610386-8A priority patent/BR9610386A/pt
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med, Bruno Tocque, Dubs Poterszman Marie Christin, Bohdan Wasylyk filed Critical Rhone Poulenc Rorer Sa
Priority to AT96930195T priority patent/ATE257711T1/de
Priority to HU9900406A priority patent/HU223597B1/hu
Priority to AU69334/96A priority patent/AU722782B2/en
Publication of WO1997009343A2 publication Critical patent/WO1997009343A2/fr
Publication of WO1997009343A3 publication Critical patent/WO1997009343A3/fr
Priority to MXPA/A/1998/001407A priority patent/MXPA98001407A/xx
Priority to NO19980905A priority patent/NO319160B1/no
Priority to US13/835,524 priority patent/US20140030319A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé capable d'antagoniser au moins partiellement l'activité oncogénique de la protéine Mdm2 pour la préparation d'une composition pharmaceutique destinée plus particulièrement au traitement des cancers à contexte p53 nul. Elle se rapporte en outre à un vecteur viral comprenant une séquence d'acide nucléique codant pour un composé capable d'inhiber au moins partiellement l'activité oncogénique de la protéine Mdm2 et à une composition pharmaceutique correspondante.
PCT/FR1996/001340 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers WO1997009343A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR9610386-8A BR9610386A (pt) 1995-09-04 1996-09-02 Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica
DE69631335T DE69631335T2 (de) 1995-09-04 1996-09-02 Antagonisten der onkogenen aktivität von mdm2, und ihre verwendung in der krebsbehandlung
SK280-98A SK287127B6 (sk) 1995-09-04 1996-09-02 Antagonisty onkogénnej aktivity proteínu Mdm2 a ich použitie na liečenie rakovín
IL123514A IL123514A (en) 1995-09-04 1996-09-02 Pharmacological preparations for cancer containing antagonists of the oncogenic activity of the protein Mdm2
CA2228667A CA2228667C (fr) 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
JP9510900A JPH11511980A (ja) 1995-09-04 1996-09-02 Ｍｄｍ２タンパク質の腫瘍原活性のアンタゴニスト及び癌治療におけるその使用
SI9630666T SI0848720T1 (en) 1995-09-04 1996-09-02 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers
DK96930195T DK0848720T3 (da) 1995-09-04 1996-09-02 Antagonister af den onkogene aktivitet af proteinet Mdm2 og deres anvendelse ved behandling af cancere
AT96930195T ATE257711T1 (de) 1995-09-04 1996-09-02 Antagonisten der onkogenen aktivität von mdm2, und ihre verwendung in der krebsbehandlung
EP96930195A EP0848720B1 (fr) 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
HU9900406A HU223597B1 (hu) 1995-09-04 1996-09-02 Az MDM2 protein onkogén hatásának antagonistái és felhaszlálásuk rák kezelésére
AU69334/96A AU722782B2 (en) 1995-09-04 1996-09-02 Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
MXPA/A/1998/001407A MXPA98001407A (en) 1995-09-04 1998-02-20 Antagonists of the oncogenic activity of the mdm2 protein, and its use in the treatment of the cance
NO19980905A NO319160B1 (no) 1995-09-04 1998-03-02 Anvendelse av forbindelser som kan antagonisere den oncogeniske aktivitet av proteinet mdm2, anvendelse av en nukleinsyre som koder for slike forbindelser, en viral vektor, et farmasoytisk preparat, samt anvendelse av en nukleinsyresekvens som koder for intracellulaere antistoffer.
US13/835,524 US20140030319A1 (en) 1995-09-04 2013-03-15 Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510331A FR2738151B1 (fr) 1995-09-04 1995-09-04 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FR95/10331 1995-09-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/029,327 A-371-Of-International US20030060432A1 (en) 1995-09-04 1996-09-02 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers
US10/724,225 Division US20040209834A1 (en) 1995-09-04 2003-12-01 Antagonists of the oncogenic activity of the MDM2, and use thereof in the treatment of cancers

Publications (2)

Publication Number Publication Date
WO1997009343A2 WO1997009343A2 (fr) 1997-03-13
WO1997009343A3 true WO1997009343A3 (fr) 1997-05-29

Family

ID=9482234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1996/001340 WO1997009343A2 (fr) 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers

Country Status (20)

Country Link
US (4) US20030060432A1 (fr)
EP (1) EP0848720B1 (fr)
JP (2) JPH11511980A (fr)
KR (1) KR100592916B1 (fr)
AT (1) ATE257711T1 (fr)
AU (1) AU722782B2 (fr)
BR (1) BR9610386A (fr)
CA (1) CA2228667C (fr)
CZ (1) CZ298806B6 (fr)
DE (1) DE69631335T2 (fr)
DK (1) DK0848720T3 (fr)
ES (1) ES2210386T3 (fr)
FR (1) FR2738151B1 (fr)
HU (1) HU223597B1 (fr)
IL (1) IL123514A (fr)
NO (1) NO319160B1 (fr)
PT (1) PT848720E (fr)
SK (1) SK287127B6 (fr)
WO (1) WO1997009343A2 (fr)
ZA (1) ZA967451B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
US6013786A (en) * 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (fr) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Dérivés d'acide phénoxyacétique et phénoxymethyltetrazole à activité antitumorale
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
DE10109813A1 (de) * 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
CA2939778C (fr) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US20090018078A1 (en) * 2007-07-09 2009-01-15 Vinod Labhasetwar Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
MX391175B (es) 2010-08-13 2025-03-21 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CA2852468A1 (fr) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
EP2819688A4 (fr) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Macrocycles peptidomimétiques réticulés par triazole et par thioéther
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
EP2914256B1 (fr) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
US11279934B2 (en) * 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
EP3197477A4 (fr) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et formulations de ceux-ci
EP3197478A4 (fr) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
WO2016154058A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
CN111491661B (zh) * 2017-07-27 2024-11-01 诺莫坎制药有限责任公司 M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
WO2020159504A1 (fr) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Anticorps dirigés contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer
WO2020023502A1 (fr) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et utilisations associées
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations
CN118421627A (zh) * 2024-04-28 2024-08-02 上海雅义生物医药科技有限公司 一种抑制mdm2和mdm4基因扩增的三链形成寡核苷酸序列及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020238A2 (fr) * 1992-04-07 1993-10-14 The Johns Hopkins University Amplification du gene mdm2 dans des tumeurs chez l'homme
WO1994029446A2 (fr) * 1993-06-16 1994-12-22 Rhone-Poulenc Rorer S.A. Proteines intracellulaires de liaison (pil) et leurs utilisations
WO1996002642A1 (fr) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION DE LA LIAISON DE LA PROTEINE MDM2 ET p53 ET SON APPLICATION THERAPEUTIQUE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2137822C (fr) * 1992-06-26 2009-01-20 Arnold J. Levine Methode de detection de cellules precancereuses et cancereuses a l'aide d'anticorps p90 et de sondes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020238A2 (fr) * 1992-04-07 1993-10-14 The Johns Hopkins University Amplification du gene mdm2 dans des tumeurs chez l'homme
WO1994029446A2 (fr) * 1993-06-16 1994-12-22 Rhone-Poulenc Rorer S.A. Proteines intracellulaires de liaison (pil) et leurs utilisations
WO1996002642A1 (fr) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION DE LA LIAISON DE LA PROTEINE MDM2 ET p53 ET SON APPLICATION THERAPEUTIQUE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIANDONG CHEN ET AL.: "MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS.", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 7, July 1993 (1993-07-01), pages 4107 - 4114, XP000571629 *
PING LENG ET AL.: "HUMAN ONCOPROTEIN MDM2 INTERACTS WITH THE TATA-BINDING PROTEIN IN VITRO AND IN VIVO", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 6, no. 1, January 1995 (1995-01-01), pages 251 - 259, XP002004851 *
THIERRY LŸVEILLARD ET AL.: "THE ONCOPROTEIN MDM2 ASSOCIATES WITH THE TATA-BINDING PROTEIN (TBP).", JOURNAL OF CELLULAR BIOCHEMISTRY, no. SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 54, XP000572208 *

Also Published As

Publication number Publication date
KR19990044356A (ko) 1999-06-25
CZ298806B6 (cs) 2008-02-06
US20140030319A1 (en) 2014-01-30
DE69631335T2 (de) 2004-12-02
ZA967451B (en) 1997-03-10
CA2228667A1 (fr) 1997-03-13
ATE257711T1 (de) 2004-01-15
BR9610386A (pt) 1999-10-13
IL123514A0 (en) 1998-10-30
EP0848720B1 (fr) 2004-01-14
US20080311608A1 (en) 2008-12-18
JPH11511980A (ja) 1999-10-19
JP2011225571A (ja) 2011-11-10
IL123514A (en) 2006-10-31
US20040209834A1 (en) 2004-10-21
HUP9900406A2 (hu) 1999-05-28
DE69631335D1 (de) 2004-02-19
US20030060432A1 (en) 2003-03-27
MX9801407A (es) 1998-05-31
ES2210386T3 (es) 2004-07-01
EP0848720A2 (fr) 1998-06-24
WO1997009343A2 (fr) 1997-03-13
AU722782B2 (en) 2000-08-10
NO980905L (no) 1998-03-02
AU6933496A (en) 1997-03-27
DK0848720T3 (da) 2004-04-19
SK28098A3 (en) 1998-08-05
PT848720E (pt) 2004-05-31
NO319160B1 (no) 2005-06-27
NO980905D0 (no) 1998-03-02
HU223597B1 (hu) 2004-10-28
HUP9900406A3 (en) 2002-04-29
CZ63098A3 (cs) 1998-06-17
FR2738151A1 (fr) 1997-03-07
CA2228667C (fr) 2013-06-04
KR100592916B1 (ko) 2006-11-07
SK287127B6 (sk) 2009-12-07
FR2738151B1 (fr) 1997-09-26

Similar Documents

Publication Publication Date Title
WO1997009343A3 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
HUP9602507A3 (en) Cyclic peptides, adhesion inhibitor pharmaceutical compositions comprising the compounds, process for the preparation of the compounds and the pharmaceutical compositions and the use of the compounds
CA2333145A1 (fr) Dispositif de liberation de medicaments comprenant un peptide a homeoboite et un composant de liberation de nature non peptidique et non nucleotidique
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0100280A3 (en) Pyrrolo-, thieno-, furano- and pyrazolo- [3,4d]-pyridazinones, process for their preparation and pharmaceutical compositions containing them
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
EP0300189A3 (en) New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
HU0301171D0 (en) Antifungal active ingredients, pharmaceutical compositions containing the same and process for their preparation
EP0695171A1 (fr) Lyospheres contenant de la gonadotrophine
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
CA2114313A1 (fr) Peptides bpc, leur preparation et utilisation
AU2974189A (en) Pharmaceutical compositions containing lactams, new substituted lactams and processes for the preparation thereof
WO1999059609A3 (fr) Utilisation de proteines hmg pour l'elaboration de medicaments a activite cytotoxique
ZA983997B (en) Triazole derivatives, process for their preparation and pharmaceutical compositions containing them.
EP0791601A3 (fr) Agent améliorant la formation d'os et inhibitant la résorption osseuse
ZA989781B (en) Novel bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them.
HUP0000952A3 (en) Carbapenem compounds, process for their preparation and pharmaceutical compositions containing them
ZA978083B (en) Modified amino acids, medicaments containing these compounds and processes for their preparation.
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
HRP960076B1 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds, as well as medicaments containing them
AU1728197A (en) Lipopolyamine compound, pharmaceutical composition and nucleic acid transfer vector containing same, and preparation method
WO2000006735A8 (fr) HYBRIDES D'INTERFERON-$g(a)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/001407

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2228667

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2228667

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 28098

Country of ref document: SK

Ref document number: PV1998-630

Country of ref document: CZ

Ref document number: 1019980701598

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1997 510900

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996930195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09029327

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV1998-630

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996930195

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980701598

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996930195

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019980701598

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1998-630

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载